Baird lowered the firm’s price target on Revvity (RVTY) to $127 from $141 and keeps an Outperform rating on the shares. The firm upated its ...

For further information on Revvity’s cancer research innovations and poster presentations at the AACR Annual Meeting 2025, visit booth #1200 or this link. All Revvity offerings mentioned herein ...